Back to News

Aragen’s Formulation Manufacturing Facility Achieves GMP Certification from Telangana Drugs Control Administration

May 17, 2024

Certification Marks a Milestone for Aragen, Reinforcing Commitment to Quality and Regulatory Compliance in Pharmaceutical Manufacturing.

Aragen is pleased to announce that its Formulation Manufacturing Facility (FMF) has been awarded Good Manufacturing Practice (GMP) certification by the Drugs Control Administration (DCA) of Telangana. This significant achievement underscores our commitment to the highest standards of quality and compliance within the pharmaceutical manufacturing sector.

The GMP certification is a clear indication of Aragen’s adherence to rigorous regulatory standards and its commitment to maintaining the highest levels of product quality and safety. Our state-of-the-art Formulations Manufacturing Facility is meticulously designed to support the clinical batch production of new chemical entities across a variety of dosage forms, including oral solids, liquids, topicals, and films.

Spokes Person at Aragen, stated, “This certification is a testament to our team’s hard work and dedication to excellence. It enhances our capabilities to serve as a trusted partner in the pharmaceutical industry, offering integrated concept-to-clinic solutions that meet the dynamic needs of our clients.”

As Aragen continues to drive innovation and operational excellence, this GMP certification further strengthens our ability to deliver high-quality, compliant, and effective pharmaceutical products. Our unwavering commitment to quality ensures that we can confidently say, “In every molecule, there is the possibility of better health.”

Source: BioPharma